Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture and market its generic version of metoprolol tartrate tablets used to treat high blood pressure.
The approval granted by the United States Food and Drug Administration (USFDA) is for metoprolol tartrate tablets of strengths 25 mg, 50 mg, and 100 mg, Zydus Lifesciences said in a regulatory filing.
The drug will be manufactured at the group's formulation manufacturing facility at Baddi in Himachal Pradesh, it added.
Metoprolol is used with or without other medications to treat high blood pressure (hypertension), the company said, adding the medication is also used to treat chest pain (angina) and to improve survival after a heart attack.
Metoprolol tartrate tablets 25 mg, 50 mg, and 100 mg had annual sales of USD 45.2 million in the US, the company said citing IQVIA MAT February 2023 data.
India's 5G tablet shipments grow 61% QoQ in Q3 of Calendar 2022: CMR report
'India believes in democratized access to all digital health solutions'
Dr Reddy's, Cipla, and Aurobindo units recall products in US market
Tablet PC market grows 22% in Jul-Sep quarter; Samsung leads: Report
HMD Global launches Unisoc T612-powered Nokia T21 tablet: Know price, specs
Hybrid solar eclipse 2023: When, where and how to see rare celestial event
Tesla chief Elon Musk threatens to sue Microsoft for using data 'illegally'
First hybrid solar eclipse in a decade begins; it won't be visible in India
India races to get rich before it gets old as population surpasses China's
Deadly heat bakes millions from China to India, raising blackout risks
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)